Archives
-
GOB-38 in Elizabethkingia: Substrate Specificity
2026-09-29
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, and shows that it hydrolyzes penicillins, multiple cephalosporin generations, and carbapenems. Its recombinant-enzyme, genomic, and co-culture evidence connects active-site variation with broad β-lactam resistance and raises cautious concerns about resistance exchange during polymicrobial infection.
-
Pepstatin A for Reliable Cell Assays
2026-09-29
Learn how Pepstatin A (SKU A2571) can support better-controlled viability, proliferation, cytotoxicity, osteoclast, and viral protein-processing experiments. This scenario-based guide covers target selection, DMSO compatibility, treatment windows, orthogonal validation, and practical supplier evaluation.
-
Biomimetic Nanoplatform for Metastatic TNBC
2026-09-28
This ACS Nano study presents a biomimetic nanoplatform that combines 980 nm photothermal ablation with tumor-targeted delivery of the immune adjuvant R848 and an acid-responsive anti-PD-1 peptide. Its central contribution is the integration of primary tumor destruction, tumor-antigen release, and immune remodeling into one dendritic large-pore mesoporous silica nanoparticle system for metastatic triple-negative breast cancer.
-
Ruxolitinib in Sarcoma Immune-Profiling Workflows
2026-09-28
Ruxolitinib (INCB018424) offers a practical way to test how JAK1/2 blockade reshapes tumor and immune-cell responses, including in combination with oncolytic HSV. A murine sarcoma study shows why pairing treatment with high-dimensional spectral flow cytometry can reveal CD4 T-cell and germinal-center B-cell changes that narrower panels may miss.
-
From Reporter Signal to Lung-Targeted RNA Translation
2026-09-27
A practical framework for using Gaussia luciferase mRNA to interrogate LNP delivery, interpret reporter output, and connect formulation screening with the emerging design principles of lung-targeted RNA medicines.
-
Mutant p53-R280K Drives FASN-Dependent Breast Cancer
2026-09-26
A 2026 study reports that mutant p53-R280K partners with SREBP1 to activate FASN, increasing fatty acid synthesis and promoting breast cancer phenotypes in cell and mouse models. The findings define a p53-R280K/SREBP1/FASN pathway as a candidate metabolic vulnerability, while leaving its clinical relevance and transferability to other tumor contexts to be tested.
-
TAK-715: Interpreting p38 Inhibition Precisely
2026-09-25
TAK-715 is a potent p38 MAPK inhibitor for studying inflammatory signaling. This article explains how to distinguish reduced kinase output from changes in p38α phosphorylation—and why that distinction matters when interpreting cytokine and dephosphorylation assays.
-
Chloroquine Diphosphate for Autophagy Assays
2026-09-25
Use Chloroquine Diphosphate to perturb late-stage autophagy, test chemotherapy or radiotherapy sensitization, and distinguish autophagosome accumulation from completed flux. This workflow pairs dose-finding with orthogonal immune and cell-death readouts, helping cancer researchers interpret effects without treating one marker as proof of mechanism.
-
Cannabis Terpenes Engage A2A Receptors in Neuropathic Pain
2026-09-24
Schwarz and colleagues report that five Cannabis sativa terpenes reduced pain-related behavior in mouse models, with pharmacological, genetic, and cellular evidence implicating adenosine A2A receptors. The work offers a mechanistic basis for further terpene analgesia research, while leaving important questions about dose, delivery, durability, and translation to humans unresolved.
-
Nitrocefin Assays for β-Lactamase Research
2026-09-24
Use Nitrocefin’s rapid yellow-to-red response to measure β-lactamase activity, compare samples, and screen candidate inhibitors. This practical guide connects assay design to GOB-38 research while explaining why a positive Nitrocefin result is a focused enzyme readout—not a complete antibiotic-resistance profile.
-
SP2509 Workflows for LSD1-Driven AML Research
2026-09-23
SP2509 supports mechanism-led studies of LSD1 inhibition, H3K4 methylation, apoptosis, and differentiation in acute myeloid leukemia models. This guide pairs a practical dose-finding workflow with chromatin and cell-phenotype readouts, while distinguishing established product data from experimental starting points.
-
SR-202: PPARγ Antagonism in Metabolic Research
2026-09-23
SR-202 gives researchers a selective way to test whether PPARγ activity drives adipogenesis, insulin resistance, and immune-metabolic signaling. Its antagonist profile complements activation studies and supports controlled workflows spanning reporter assays, adipocyte models, and macrophage polarization.
-
Triiodothyronine (T3) in Adipose Thermogenesis
2026-09-22
Triiodothyronine (T3) is more than a thyroid hormone reagent: it is a mechanistically informative probe for connecting nuclear receptor signaling with adipose thermogenesis. This article integrates the SETD7 adipose-browning study with practical experimental strategy, assay design, translational interpretation, and responsible use of high-purity T3 in metabolic disorder research.
-
Netrin-1, Adipogenesis, and Metabolic Remodeling
2026-09-22
The reference study identifies adipose-derived Netrin-1 as a negative regulator of compensatory adipose remodeling during high-fat feeding. Through loss- and gain-of-function mouse models, cellular analyses, and pathway investigation, it links Netrin-1 to impaired PPARγ activity, increased Wnt/β-catenin signaling, reduced adipogenesis, and poorer glucose tolerance.
-
Thiamet G: O-GlcNAc Signaling in Bone
2026-09-21
Thiamet G is an O-GlcNAcase inhibitor that reveals how dynamic O-GlcNAcylation connects Wnt signaling, glycolysis, tau biology, and therapeutic sensitization. This article translates a recent bone-formation study into practical assay-design decisions without treating pathway activation as a single static endpoint.